ArticleThe Lancet. Infectious diseases2024
Viral shedding and viraemia of Andes virus during acute hantavirus infection: a prospective study.
Article in The Lancet. Infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
- Pooled it
- Hantavirus preparedness at human-rodent interfaces: lessons from China's HFRS control and Andes virus transmission in mobile populations.Emerging microbes & infections · 2026Review
- Article
- Review
- Hantavirus in Dentistry: Occupational Exposure Considerations and a Proposed Tiered Infection Prevention and Control Framework-A Narrative Review.Clinical and experimental dental research · 2026Review
- Andes Virus: From Transmission Dynamics to Pandemic Potential.European journal of clinical investigation · 2026Review
- The Changing Landscape of Hantavirus Infections: A Narrative Review of Epidemiology, Pathogenesis, and Countermeasures.Reviews in medical virology · 2026Review
- Andes hantavirus in South America: Emerging epidemiological trends, regional challenges, and lessons beyond the MV Hondius outbreak.New microbes and new infections · 2026Article
- Ribavirin post-exposure prophylaxis for Andes virus exposure: a viewpoint.EBioMedicine · 2026Review
- Hanta on the Hondius - public health and bioethical perspectives of the recentNew microbes and new infections · 2026Article
- Detectability of Pathogenic RNA Virus Families in Different Body Sites: A Scoping Review.Viruses · 2026Article
- Hantavirus Cluster Linked to Cruise Ship Travel: A Comprehensive Review of a Looming Global Public Health Concern.Cureus · 2026Review
- TheThe Lancet regional health. Europe · 2026Article
- Three Decades of Hantavirus Management in Chile: Lessons for Europe.The Lancet regional health. Europe · 2026Article
- Preparing Europe for imported Andes virus: the role of rapid serology and molecular diagnostics.The Lancet regional health. Europe · 2026Article
- Article
- Human Orthohantavirus Infections: A Narrative Review.Pathogens (Basel, Switzerland) · 2026Review
- Andes hantavirus - A primer.Npj viruses · 2026Article
- Andes virus and the aging host: lessons from the 2026 outbreak and a framework for age-related disease severity.GeroScience · 2026Review
- Why Andes hantavirus is not the next SARS-CoV-2: contrasting viral shedding, transmissibility and genomic patterns.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
Corrections and comments
- Commented on by
- Erratum issued
- Erratum issued
Authors and funding
25 authors at 10 institutions in 2 countries.
Funding
Abstract
backgroundAndes virus (ANDV) is a zoonotic Orthohantavirus leading to hantavirus cardiopulmonary syndrome. Although most transmissions occur through environmental exposure to rodent faeces and urine, rare person-to-person transmission has been documented, mainly for close contacts. This study investigates the presence and infectivity of ANDV in body fluids from confirmed cases and the duration of viraemia.
methodsIn this prospective study, 131 participants with confirmed ANDV infection were enrolled in Chile in a prospective study between 2008 and 2022. Clinical samples (buffy coat, plasma, gingival crevicular fluid [GCF], saliva, nasopharyngeal swabs [NPS], and urine) were collected weekly for 3 weeks together with clinical and epidemiological data. Samples were categorised as acute or convalescent (up to and after 16 days following onset of symptoms). Infectivity of positive fluids was assessed after the culture of samples on Vero E6 cells and use of flow cytometry assays to determine the production of ANDV nucleoprotein.
findingsANDV RNA was detected in 100% of buffy coats during acute phase, declining to 95% by day 17, and to 93% between days 23-29. ANDV RNA in GCF and saliva decreased from 30% and 12%, respectively, during the acute phase, to 12% and 11% during the convalescent phase. Successful infectivity assays of RT-qPCR-positive fluids, including GCF, saliva, NPS, and urine, were observed in 18 (42%) of 43 samples obtained during the acute phase of infection. After re-culture, the capacity to infect Vero E6 cells was maintained in 16 (89%) of 18 samples. Severity was associated with the presence of ANDV RNA in one or more fluids besides blood (odds ratio 2·58 [95% CI 1·42-5·18]).
interpretationANDV infection is a systemic and viraemic infection, that affects various organs. The presence of infectious particles in body fluids contributes to our understanding of potential mechanisms for person-to-person transmission, supporting the development of preventive strategies. Detection of ANDV RNA in additional fluids at hospital admission is a predictor of disease severity.
fundingNational Institutes of Health and Agencia de Investigación y Desarrollo. TRANSLATION: For the Spanish translation of the abstract see Supplementary Materials section.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.